The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework

Moltzan, Catherine; Anderson, David R.; Callum, Jeannie; Fremes, Stephen; Hume, Heather; Mazer, C. David; Mc, Poon; Rivard, Georges‐Étienne; Rizoli, Sandro; Robinson, S.

doi:10.1111/j.1365-3148.2012.01164.x

Cited by 35 publications

(15 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is not routinely recommended in our protocol, but it is given on compassionate basis at the discretion of the trauma surgeon. The use of rVIIa in trauma is less common as recent evidence has not shown improved patient outcomes in the bleeding trauma patients but confirmed significant risk of thrombotic side effects [15]. Following publication of CRASH-II study, tranexamic acid has been added to our MTP [16].…”

Section: Discussionmentioning

confidence: 93%

Compliance with a massive transfusion protocol (MTP) impacts patient outcome

Bawazeer

Ahmed²,

Izadi³

et al. 2015

Injury

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Compliance with a massive transfusion protocol (MTP) impacts patient outcome

Bawazeer

Ahmed²,

Izadi³

et al. 2015

Injury

View full text Add to dashboard Cite

“…Cost‐effectiveness analysis has also shown significant incremental cost associated with rfVIIa use in massive transfusion. (Ho & Litton, ) These considerations led the Canadian National Advisory Committee on Blood Products to recommend against use of rfVIIa in non‐haemophilic bleeding (Lin et al , ). rfVIIa has subsequently been removed from the hospital MTP.…”

Section: Discussionmentioning

confidence: 99%

Not only in trauma patients: hospital‐wide implementation of a massive transfusion protocol

Kreuziger

Morton

Subramanian

et al. 2013

Transfusion Medicine

View full text Add to dashboard Cite

Objectives To review outcomes of massive transfusion protocol (MTP) activation and determine the impact of MTP implementation on blood bank use. Background MTP has been established to rapidly provide plasma and packed red blood cells in ratios approaching 1:1. Due to availability, MTP has been utilized in non-traumatic hemorrhage despite evidence of benefit in this population. Our hospital wide implementation of MTP was reviewed for propriety, outcomes, and effect on blood bank resources. Methods Retrospective cohort study of patients receiving transfusion after MTP activation from October 2009- 2011. Underlying medical conditions and baseline medication use were determined. In-hospital and 24-hour mortality were compared with evaluation for confounding by APACHE score and duration of MTP activation. Blood product use before and after MTP implementation was reviewed. Results MTP activation occurred in 62 trauma and 63 non-trauma patients. Non-trauma patients were older, had more underlying medical conditions, and higher APACHE scores compared to trauma patients. 24-hour mortality was higher in trauma compared to non-trauma patients (27.4% vs. 11.1%, p =0.02). There was no significant difference of in-hospital mortality. Transfusion ratio did not differ between trauma and non-trauma patients and was not associated with mortality even when MTP activation duration and APACHE score were considered. Hospital-wide blood product use did not change with MTP implementation. Conclusions MTP may be successfully used in trauma and non-trauma settings without significantly impacting overall blood product utilization. Inclusion of non-trauma patients into prospective studies of resuscitation with blood products is warranted to ensure benefit in these patients.

show abstract

“…More than 50% of hemorrhagic stroke patients die in the early stage (Bamford et al, 1990; Fogelholm et al, 1992). The effectiveness of the management for controlling bleeding and blood pressure remains questionable (Lin et al, 2012; Qureshi et al, 2014). Surgical approaches for hematoma evacuation either through open craniotomy or endoscopy in the acute phase may reduce mortality (Dastur and Yu, 2017; Siddique and Mendelow, 2000).…”

Section: Introductive Remarks: the Importance Of Enhancing Stroke Recmentioning

confidence: 99%

Enhancing endogenous capacity to repair a stroke-damaged brain: An evolving field for stroke research

Zhao

Willing

2018

Progress in Neurobiology

102

View full text Add to dashboard Cite

Stroke represents a severe medical condition that causes stroke survivors to suffer from long-term and even lifelong disability. Over the past several decades, a vast majority of stroke research targets neuroprotection in the acute phase, while little work has been done to enhance stroke recovery at the later stage. Through reviewing current understanding of brain plasticity, stroke pathology, and emerging preclinical and clinical restorative approaches, this review aims to provide new insights to advance the research field for stroke recovery. Lifelong brain plasticity offers the long-lasting possibility to repair a stroke-damaged brain. Stroke impairs the structural and functional integrity of entire brain networks; the restorative approaches containing multi-components have great potential to maximize stroke recovery by rebuilding and normalizing the stroke-disrupted entire brain networks and brain functioning. The restorative window for stroke recovery is much longer than previously thought. The optimal time for brain repair appears to be at later stage of stroke rather than the earlier stage. It is expected that these new insights will advance our understanding of stroke recovery and assist in developing the next generation of restorative approaches for enhancing brain repair after stroke.

show abstract

The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework

Cited by 35 publications

References 38 publications

Compliance with a massive transfusion protocol (MTP) impacts patient outcome

Compliance with a massive transfusion protocol (MTP) impacts patient outcome

Not only in trauma patients: hospital‐wide implementation of a massive transfusion protocol

Enhancing endogenous capacity to repair a stroke-damaged brain: An evolving field for stroke research

Contact Info

Product

Resources

About